US Biotech Company Announces “Positive Interim” Phase 1 for Potential Vaccine Against COVID-19
Moderna, Inc., a clinical-stage biotechnology company situated in Massachusetts, United States, has announced positive Interim Phase 1 data for mRNA-1273, a potential vaccine against Novel Coronavirus (COVID-19), through a press release published yesterday, May 18, 2020.
The Interim Phase 1 Data
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 µg. When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”
– Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna
Phase 3 Study to Start in July
Moreover, according to the Chief Executive Officer at Moderna, Stéphane Bancel, with today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start their pivotal Phase 3 study in July.
In addition, the Moderna CEO also stated that they are investing to scale up manufacturing in order to maximize the number of doses they can produce to help protect as many people as they can from SARS-CoV-2, the virus that causes COVID-19.
The First Human Clinical Trial for Moderna’s COVID-19 Vaccine
Earlier this March, Moderna, Inc. started the first human clinical trial for their potential COVID-19 vaccine, with Four (4) of their volunteers receiving their first two shots of the vaccine.
For More News and Updates
Stay updated with the latest news, updates, and inspiring stories within Baguio City and Beyond! Follow our official Baguio City Guide Facebook page or simply check the rest of our website content here.
SOURCE Moderna, Inc.